The use of cyclosporine in high-risk keratoplasty.
In a study of three groups of high-risk keratoplasty patients, Group A (n = 19) received topical corticosteroids only; two grafts (10.5%) survived. Group B (n = 20) received both topical and systemic corticosteroids; one graft (5%) survived. There was no significant difference between Group A and Group B (P = .8095). Group C (n = 18) received systemic cyclosporine in addition to topical and systemic corticosteroids; 16 grafts (88.9%) survived, which was a significant improvement compared to results in the other two groups (P = .0001). No patient suffered any permanent side effects related to the use of cyclosporine.
Hill
J C
JC
Department of Ophthalmology, Groote Schuur Hospital, Cape Town, South Africa.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D016039:Corneal Transplantation; D003524:Cyclosporins / Q000097:blood / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D011182:Postoperative Care; D011446:Prospective Studies; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D003524:Cyclosporins